vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Apple Hospitality REIT, Inc.（APLE）财务数据对比。点击上方公司名可切换其他公司
Apple Hospitality REIT, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.8倍（$337.7M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 8.2%，领先5.1%），Apple Hospitality REIT, Inc.同比增速更快（3.1% vs -1.8%），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -6.9%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
莱曼 hospitality properties是一家深耕酒店、度假村、娱乐及媒体领域的企业，得名于旗下核心资产——位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾作为爱德华·盖洛德旗下俄克拉荷马出版公司子公司的时期，1983年收购WSM公司后，拿下大奥普里等知名IP，奠定了如今的业务发展基础。
AMPH vs APLE — 直观对比
营收规模更大
APLE
是对方的1.8倍
$183.1M
营收增速更快
APLE
高出4.9%
-1.8%
净利率更高
AMPH
高出5.1%
8.2%
两年增速更快
AMPH
近两年复合增速
-6.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $337.7M |
| 净利润 | $24.4M | $27.7M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 14.2% |
| 净利率 | 13.3% | 8.2% |
| 营收同比 | -1.8% | 3.1% |
| 净利润同比 | -35.7% | 12.7% |
| 每股收益（稀释后） | $0.51 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHAPLE
| Q1 26 | — | $337.7M | ||
| Q4 25 | $183.1M | $326.4M | ||
| Q3 25 | $191.8M | $373.9M | ||
| Q2 25 | $174.4M | $384.4M | ||
| Q1 25 | $170.5M | $327.7M | ||
| Q4 24 | $186.5M | $333.0M | ||
| Q3 24 | $191.2M | $378.8M | ||
| Q2 24 | $182.4M | $390.1M |
净利润AMPHAPLE
| Q1 26 | — | $27.7M | ||
| Q4 25 | $24.4M | $29.6M | ||
| Q3 25 | $17.4M | $50.9M | ||
| Q2 25 | $31.0M | $63.6M | ||
| Q1 25 | $25.3M | $31.2M | ||
| Q4 24 | $38.0M | $29.8M | ||
| Q3 24 | $40.4M | $56.3M | ||
| Q2 24 | $37.9M | $73.9M |
毛利率AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | 37.2% | ||
| Q3 25 | 51.4% | 40.6% | ||
| Q2 25 | 49.6% | 42.6% | ||
| Q1 25 | 50.0% | 39.0% | ||
| Q4 24 | 46.5% | 38.6% | ||
| Q3 24 | 53.3% | 41.9% | ||
| Q2 24 | 52.2% | 44.6% |
营业利润率AMPHAPLE
| Q1 26 | — | 14.2% | ||
| Q4 25 | 19.4% | 15.2% | ||
| Q3 25 | 13.2% | 19.4% | ||
| Q2 25 | 24.2% | 22.1% | ||
| Q1 25 | 21.9% | 15.5% | ||
| Q4 24 | 24.2% | 15.0% | ||
| Q3 24 | 29.8% | 20.5% | ||
| Q2 24 | 30.3% | 24.0% |
净利率AMPHAPLE
| Q1 26 | — | 8.2% | ||
| Q4 25 | 13.3% | 9.1% | ||
| Q3 25 | 9.0% | 13.6% | ||
| Q2 25 | 17.8% | 16.6% | ||
| Q1 25 | 14.8% | 9.5% | ||
| Q4 24 | 20.4% | 9.0% | ||
| Q3 24 | 21.1% | 14.9% | ||
| Q2 24 | 20.8% | 19.0% |
每股收益（稀释后）AMPHAPLE
| Q1 26 | — | $0.12 | ||
| Q4 25 | $0.51 | $0.13 | ||
| Q3 25 | $0.37 | $0.21 | ||
| Q2 25 | $0.64 | $0.27 | ||
| Q1 25 | $0.51 | $0.13 | ||
| Q4 24 | $0.74 | $0.13 | ||
| Q3 24 | $0.78 | $0.23 | ||
| Q2 24 | $0.73 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $7.8M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $3.1B |
| 总资产 | $1.6B | $4.9B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHAPLE
| Q1 26 | — | $7.8M | ||
| Q4 25 | $282.8M | $8.5M | ||
| Q3 25 | $276.2M | $50.3M | ||
| Q2 25 | $231.8M | $7.9M | ||
| Q1 25 | $236.9M | $14.9M | ||
| Q4 24 | $221.6M | $10.3M | ||
| Q3 24 | $250.5M | $6.1M | ||
| Q2 24 | $217.8M | $7.2M |
总债务AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $1.5B | ||
| Q3 25 | $608.6M | $1.5B | ||
| Q2 25 | $607.7M | $1.5B | ||
| Q1 25 | $603.9M | $1.5B | ||
| Q4 24 | $601.6M | $1.5B | ||
| Q3 24 | $596.4M | $1.5B | ||
| Q2 24 | $586.9M | $1.5B |
股东权益AMPHAPLE
| Q1 26 | — | $3.1B | ||
| Q4 25 | $788.8M | $3.1B | ||
| Q3 25 | $776.7M | $3.2B | ||
| Q2 25 | $757.5M | $3.2B | ||
| Q1 25 | $751.3M | $3.2B | ||
| Q4 24 | $732.3M | $3.3B | ||
| Q3 24 | $727.7M | $3.3B | ||
| Q2 24 | $713.3M | $3.3B |
总资产AMPHAPLE
| Q1 26 | — | $4.9B | ||
| Q4 25 | $1.6B | $4.9B | ||
| Q3 25 | $1.7B | $4.9B | ||
| Q2 25 | $1.6B | $4.9B | ||
| Q1 25 | $1.6B | $4.9B | ||
| Q4 24 | $1.6B | $5.0B | ||
| Q3 24 | $1.5B | $5.0B | ||
| Q2 24 | $1.5B | $5.1B |
负债/权益比AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 0.49× | ||
| Q3 25 | 0.78× | 0.47× | ||
| Q2 25 | 0.80× | 0.48× | ||
| Q1 25 | 0.80× | 0.48× | ||
| Q4 24 | 0.82× | 0.45× | ||
| Q3 24 | 0.82× | 0.46× | ||
| Q2 24 | 0.82× | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $370.2M | ||
| Q3 25 | $52.6M | $126.4M | ||
| Q2 25 | $35.6M | $108.8M | ||
| Q1 25 | $35.1M | $49.1M | ||
| Q4 24 | $29.0M | $405.4M | ||
| Q3 24 | $60.0M | $128.2M | ||
| Q2 24 | $69.1M | $127.3M |
自由现金流AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $282.0M | ||
| Q3 25 | $47.2M | $109.0M | ||
| Q2 25 | $25.0M | $96.2M | ||
| Q1 25 | $24.4M | $29.5M | ||
| Q4 24 | $16.6M | $327.1M | ||
| Q3 24 | $46.2M | $113.1M | ||
| Q2 24 | $63.1M | $115.0M |
自由现金流率AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 86.4% | ||
| Q3 25 | 24.6% | 29.2% | ||
| Q2 25 | 14.3% | 25.0% | ||
| Q1 25 | 14.3% | 9.0% | ||
| Q4 24 | 8.9% | 98.2% | ||
| Q3 24 | 24.1% | 29.9% | ||
| Q2 24 | 34.6% | 29.5% |
资本支出强度AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 27.0% | ||
| Q3 25 | 2.8% | 4.7% | ||
| Q2 25 | 6.1% | 3.3% | ||
| Q1 25 | 6.3% | 6.0% | ||
| Q4 24 | 6.7% | 23.5% | ||
| Q3 24 | 7.2% | 4.0% | ||
| Q2 24 | 3.3% | 3.2% |
现金转化率AMPHAPLE
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 12.50× | ||
| Q3 25 | 3.03× | 2.49× | ||
| Q2 25 | 1.15× | 1.71× | ||
| Q1 25 | 1.39× | 1.57× | ||
| Q4 24 | 0.76× | 13.59× | ||
| Q3 24 | 1.48× | 2.28× | ||
| Q2 24 | 1.82× | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APLE
| Comparable Hotels Total Revenue | $336.9M | 100% |
| RevPAR (Comparable Hotels) | $114.6K | 0% |
